NCT04476849View on ClinicalTrials.gov

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

March 6, 2022

Study Completion Date

March 11, 2022

Conditions
Healthy VolunteersRenal Impairment
Interventions
DRUG

fezolinetant

Oral

Trial Locations (7)

32720

Accel Research Sites - DeLand Clinical Research Unit, DeLand

32809

Orlando Clinical Research Center, Orlando

33765

Clinical Research of West Florida, Inc., Clearwater

55114

Prism research, LLC, Saint Paul

92377

Inland Empire Clinical Trials, LLC, Rialto

92844

National Institute of Clinical Research, Garden Grove

33014-3616

Clinical Pharmacology of Miami, LLC, Miami

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04476849 - A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function | Biotech Hunter | Biotech Hunter